Originally Posted by
broncofan
I'm going to read the New Yorker articles in the morning. Thank you. I'm interested in the subject but don't have a science background so I apologize if I get this wrong. In February I read reports that Remdesivir inhibits viral replication in vitro for the coronaviruses SARS, MERS, as well as Sars-cov-2. This is why, despite the fact that it wasn't a successful Ebola treatment, doctors in China were using it experimentally for Covid-19. That experimental use continued in the United States and there have been promising open label studies, but until yesterday there was no evidence from a controlled trial demonstrating efficacy.
Yesterday the results from a controlled trial performed by NIH were released. The endpoint was statistically significant reduction in duration of disease in people with severe Covid. I think the use of Remdesivir resulted in a reduction in the duration of the disease from 15 days to 11 days (which was statistically significant). It also reduced the mortality rate for the treated cohort but the endpoint was days to recovery. This result means it will likely get approval and be the standard treatment for the time being in patients with advanced disease.
Anyhow, most of the virologists I follow say it looks more like a step forward than a game changer. They claim that anti-virals are often most effective early in the course of illness but that Remdesivir is provided by an iv so it is only used in moderate or serious disease.
The other drug I've read about is Favipiravir, which is a flu drug used in Japan. There are ongoing trials for it and clinicians reported some benefits. I understand it's administered in pill form as well, so if it's shown to be effective in trials there is the potential people can take it at the onset of symptoms rather than once hospitalized.
I know there's been at least one negative study for an HIV combo drug called Lopinavir/Ritonavir. I'm not sure if there are more trials ongoing or that dried up all interest.
There has also been some excitement about the use of monoclonal antibodies, with a company called Regeneron preparing to conduct trials this summer. My understanding is that even if this is safe and effective, these drugs tend to be expensive to produce enough of.
Speaking of vaccines, I would not be surprised if Donald Trump endorses the idea of human challenge studies. Most doctors believe Covid-19 is too dangerous and therefore it would be unethical to perform human challenge trials to speed up Phase III testing for a vaccine. There has been some discussion of this subject among academics recently. I can imagine Trump finding this kind of dangerous shortcut attractive.